Gain/amplification of 1q21 is the most powerful genetic prognostic factor for patients treated by autologous stem cell transplantation

• Authors: NĚMEC Pavel; ZEMANOVÁ Zuzana; MICHALOVÁ Kyra; TAJTLOVÁ Jana; GREŠLIKOVÁ Henrieta; FILKOVÁ Hana; ZAORALOVÁ Romana; ŠPIČKA Ivan; GREGORA Evžen; KRÁLOVÁ Dana; KUPSKÁ Renata; KREJČÍ Marta; POUR Luděk; ZAHRADOVÁ Lenka; SANDECKÁ Viera; ADAM Zdeněk; KUGLÍK Petr; HÁJEK Roman
• Year of publication: 2008
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Our data suggest that gain1q21 is associated with reduced PFS and OS intervals in patients treated with autologous transplantation. Similarly a trend towards shorter survival for del17p13 positive patients was observed. Moreover, negative prognostic impact of gain1q21 can be boosted by presence of any other studied chromosomal aberration, which implicates much poorer outcome for patients carrying those aberrations together (data not shown). The treatment response of MM patients is not significantly influenced by any of the analyzed chromosomal abnormality. Presence of gain1q21 is significantly associated with presence of del(17p). Considering observation of unfavourable prognostic impact of gain1q21 either with or without correlation of any other studied aberrations, gain1q21 seems to be the most powerful independent prognostic factor for newly diagnosed MM patients treated by autologous stem cell transplantation.

Related projects

• Molecular basis of cell and tissue regulations
• University Research Centre - Czech Myeloma Group
• From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies